-
Talimogene laherparepvec, sold
under the
brand name
Imlygic among others, is a
biopharmaceutical medication used to
treat melanoma that
cannot be operated...
-
commercialized by
Amgen Inc. This
oncolytic herpes virus,
named Talimogene laherparepvec, has been
genetically engineered to
express human GM-CSF
using the tumor...
- variants—those
tested in
clinical trials: G207, HSV1716, NV1020 and
Talimogene laherparepvec (previously Oncovex-GMCSF).
These attenuated versions are constructed...
- 2005 for the
treatment of head and neck cancer. In 2015,
talimogene laherparepvec (OncoVex, T-VEC), an
oncolytic herpes virus which is a
modified herpes...
-
using oncolytic viruses. This
approach was used in the drug
talimogene laherparepvec, a
variant of
herpes simplex virus engineered to
selectively replicate...
- development; some
prototypes Oncolytic virus Human trials (Talimogene
laherparepvec, reolysin, JX-594),
commercialisation (H101)
Cancer therapy, imaging...
-
Niraparib and
abiraterone L01XL01
Sitimagene ceradenovec L01XL02
Talimogene laherparepvec L01XL03
Axicabtagene ciloleucel L01XL04
Tisagenlecleucel L01XL05 Ciltacabtagene...
-
cancer cells and
destroy them but not
infect healthy cells.
Talimogene laherparepvec (T-VEC), for example, is a
modified herpes simplex virus that has had...
-
Mycobacterium bovis strain for
bladder invasive cancer.
Talimogene laherparepvec (T-VEC or Imlygic) is a
vaccine for
advanced oncolytic melanoma "Preventive...
-
treatment for
adenosine deaminase deficiency (ADA-SCID)
Talimogene laherparepvec (Imlygic):
treatment for
melanoma in
people who have
recurring skin...
